(AVTR) Avantor - Ratings and Ratios
Chemicals, Reagents, Labware, Equipment, Services
Description: AVTR Avantor November 03, 2025
Avantor Inc. (NYSE:AVTR) supplies mission-critical materials, consumables, equipment, and services to biopharma, healthcare, education, government, advanced-technology, and applied-materials customers across the Americas, Europe, Asia, the Middle East, and Africa. Its portfolio spans purity chemicals, reagents, lab supplies, customized excipients and single-use assemblies, chromatography resins, analytical kits, as well as filtration, virus-inactivation, incubators, ultra-low-temperature freezers, biosafety cabinets, and peristaltic pumps.
The company also delivers on-site lab and production support, procurement and sourcing, biopharmaceutical scale-up, and a suite of scientific-research services-including DNA extraction, bioreactor servicing, compound management, clean-room monitoring, and sanitization. Founded in 1904 and headquartered in Radnor, Pennsylvania, Avantor operates under the “Life Sciences Tools & Services” GICS sub-industry.
Key financial metrics (FY 2023) show revenue of roughly $4.1 billion, an adjusted EBITDA margin near 13 %, and a 12-month forward-PE of about 18×, reflecting solid pricing power amid rising demand for biologics and personalized medicine. The sector’s growth is underpinned by expanding global biopharma pipelines, increased clinical-trial activity, and heightened focus on supply-chain resilience for critical reagents.
For a deeper quantitative assessment of Avantor’s valuation relative to peers, you may find the ValueRay platform’s forward-cash-flow model useful.
AVTR Stock Overview
| Market Cap in USD | 7,534m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2019-05-17 |
AVTR Stock Ratings
| Growth Rating | -77.7% |
| Fundamental | 48.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -57.2% |
| Analyst Rating | 3.76 of 5 |
AVTR Dividends
Currently no dividends paidAVTR Growth Ratios
| Growth Correlation 3m | 20.3% |
| Growth Correlation 12m | -80.7% |
| Growth Correlation 5y | -77.3% |
| CAGR 5y | -16.26% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.27 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.75 |
| Sharpe Ratio 12m | -0.41 |
| Alpha | -67.88 |
| Beta | 0.980 |
| Volatility | 76.30% |
| Current Volume | 8645.2k |
| Average Volume 20d | 10501k |
| Stop Loss | 10.9 (-5.9%) |
| Signal | -0.16 |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (-82.2m TTM) > 0 and > 6% of Revenue (6% = 297.1m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA -0.97pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 14.96% (prev 12.83%; Δ 2.13pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 681.8m > Net Income -82.2m (YES >=105%, WARN >=100%) |
| Net Debt (-32.1m) to EBITDA (536.6m) ratio: -0.06 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.49 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (3.24b) change vs 12m ago 373.7% (target <= -2.0% for YES) |
| Gross Margin 33.36% (prev 33.53%; Δ -0.17pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 40.39% (prev 53.11%; Δ -12.72pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.05 (EBITDA TTM 536.6m / Interest Expense TTM 174.7m) >= 6 (WARN >= 3) |
Altman Z'' 2.19
| (A) 0.06 = (Total Current Assets 2.26b - Total Current Liabilities 1.52b) / Total Assets 11.68b |
| (B) 0.19 = Retained Earnings (Balance) 2.20b / Total Assets 11.68b |
| (C) 0.07 = EBIT TTM 882.1m / Avg Total Assets 12.26b |
| (D) 0.65 = Book Value of Equity 3.95b / Total Liabilities 6.11b |
| Total Rating: 2.19 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 48.15
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield 7.41% = 3.71 |
| 3. FCF Margin 11.23% = 2.81 |
| 4. Debt/Equity 0.04 = 2.50 |
| 5. Debt/Ebitda -0.06 = 2.50 |
| 6. ROIC - WACC (= -1.06)% = -1.33 |
| 7. RoE -1.38% = -0.23 |
| 8. Rev. Trend -81.79% = -6.13 |
| 9. EPS Trend -73.55% = -3.68 |
What is the price of AVTR shares?
Over the past week, the price has changed by +0.00%, over one month by -17.81%, over three months by -0.52% and over the past year by -49.14%.
Is Avantor a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AVTR is around 8.41 USD . This means that AVTR is currently overvalued and has a potential downside of -27.37%.
Is AVTR a buy, sell or hold?
- Strong Buy: 6
- Buy: 4
- Hold: 11
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the AVTR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13.8 | 19.2% |
| Analysts Target Price | 13.8 | 19.2% |
| ValueRay Target Price | 9.5 | -18% |
AVTR Fundamental Data Overview November 01, 2025
P/E Forward = 13.9276
P/S = 1.1458
P/B = 1.4934
Beta = 0.98
Revenue TTM = 4.95b USD
EBIT TTM = 882.1m USD
EBITDA TTM = 536.6m USD
Long Term Debt = 3.23b USD (from longTermDebt, last fiscal year)
Short Term Debt = 219.8m USD (from shortTermDebt, last quarter)
Debt = 219.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -32.1m USD (from netDebt column, last quarter)
Enterprise Value = 7.50b USD (7.53b + Debt 219.8m - CCE 251.9m)
Interest Coverage Ratio = 5.05 (Ebit TTM 882.1m / Interest Expense TTM 174.7m)
FCF Yield = 7.41% (FCF TTM 555.9m / Enterprise Value 7.50b)
FCF Margin = 11.23% (FCF TTM 555.9m / Revenue TTM 4.95b)
Net Margin = -1.66% (Net Income TTM -82.2m / Revenue TTM 4.95b)
Gross Margin = 33.36% ((Revenue TTM 4.95b - Cost of Revenue TTM 3.30b) / Revenue TTM)
Gross Margin QoQ = none% (prev 32.92%)
Tobins Q-Ratio = 0.64 (Enterprise Value 7.50b / Total Assets 11.68b)
Interest Expense / Debt = 20.11% (Interest Expense 44.2m / Debt 219.8m)
Taxrate = -3.23% (negative due to tax credits) (22.3m / -689.5m)
NOPAT = 910.6m (EBIT 882.1m * (1 - -3.23%)) [negative tax rate / tax credits]
Current Ratio = 1.49 (Total Current Assets 2.26b / Total Current Liabilities 1.52b)
Debt / Equity = 0.04 (Debt 219.8m / totalStockholderEquity, last quarter 5.57b)
Debt / EBITDA = -0.06 (Net Debt -32.1m / EBITDA 536.6m)
Debt / FCF = -0.06 (Net Debt -32.1m / FCF TTM 555.9m)
Total Stockholder Equity = 5.98b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.70% (Net Income -82.2m / Total Assets 11.68b)
RoE = -1.38% (Net Income TTM -82.2m / Total Stockholder Equity 5.98b)
RoCE = 9.58% (EBIT 882.1m / Capital Employed (Equity 5.98b + L.T.Debt 3.23b))
RoIC = 8.89% (NOPAT 910.6m / Invested Capital 10.25b)
WACC = 9.95% (E(7.53b)/V(7.75b) * Re(9.63%) + D(219.8m)/V(7.75b) * Rd(20.11%) * (1-Tc(-0.03)))
Discount Rate = 9.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 118.3%
[DCF Debug] Terminal Value 71.39% ; FCFE base≈628.0m ; Y1≈584.3m ; Y5≈536.5m
Fair Price DCF = 10.81 (DCF Value 7.37b / Shares Outstanding 681.8m; 5y FCF grow -8.84% → 3.0% )
EPS Correlation: -73.55 | EPS CAGR: -12.74% | SUE: 0.0 | # QB: 0
Revenue Correlation: -81.79 | Revenue CAGR: -2.53% | SUE: 0.35 | # QB: 0
Additional Sources for AVTR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle